Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma

Phase 2TerminatedNCT03633747

Second Affiliated Hospital, School of Medicine, Zhejiang University8 enrolled

Overview

Hepatic hemangioma is one of the most common benign tumor of the liver. Although the overall prognosis is good, active interventions are still needed in high-risk patients. Without specific drugs, the main treatment methods include surgical treatments, interventional therapies and radiotherapies. Effective medical treatments are needed urgently. Propranolol has achieved good results in infantile Facial/hepatic hemangioma, and shows some effectiveness in adult hemangioma. Here, investigators intend to evaluate the therapeutic effect of propranolol in adult hepatic hemangioma.

In view of the lack of medical treatment for hepatic hemangioma, investigators chose hemangioma patients with a diameter of 5-10 cm and no significant risk of rupture, or those with surgical indications but rejected of surgical, interventional/radiological interventions. After confirmation of no high risk for drugs, oral propranolol was given. The tumor size, objective remission rate, disease control rate, drugs related side effects and other endpoints events were recorded and analyzed, to assess the propranolol could or couldn't effectively control the progress of hepatic hemangioma.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hemangioma Liver

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 to 65 years of age. * Hemangioma with a diameter of 5-10 cm, no clinical symptoms, no obvious risk of hemangioma rupture and bleeding, no obvious symptoms of tumor compression, and excluding malignant diseases; or hemangioma without surgical indications but have a strong willingness to treat; compliance with treatment indications, but refuse surgical, interventional or radiotherapy radiative interventions. * No other beta receptor modulators (activation or blockade of beta receptor signaling) were given during the previous six months. * Eastern Cooperative Oncology Group score 0-2 points. Exclusion Criteria: * Liver lesions with other malignant tumors or hepatic hemangiomas are not clearly diagnosed or have other undefined features. * Hepatic hemangioma requires surgical or radiological intervention within a limited period of time, otherwise there may be a greater risk. * Beta receptor modulator therapy is required for cardiovascular and other diseases within six months. * Previous cardiovascular or cerebrovascular events or with high risk of cardiovascular and cerebrovascular events. * Suffering from severe liver diseases such as severe cirrhosis, hepatic adenoma, liver dysfunction and so on. * Post liver transplantation. * Heart rate \< 60 beats/min, blood pressure \< 100/60 mmHg, orthostatic hypotension, cardiac insufficiency or severe cardiovascular disease (moderate to severe hypertension, coronary atherosclerotic heart disease, severe or acute heart failure, II-III atrioventricular block, ventricular tachycardia, cardiogenic shock, Raynaud syndrome or other peripheral vascular diseases). * Severe pulmonary diseases (such as bronchial asthma, emphysema), severe hematological diseases (such as agranulocytosis, thrombocytopenia), severe mental disorders (such as depression), severe thyroid diseases (hypothyroidism, hormone replacement therapy after thyroidectomy), diabetes mellitus need to be controlled by drugs. Severe kidney disease (such as nephrotic syndrome, glomerulonephritis, renal insufficiency). * Others: history of drug allergy, pregnancy or breast-feeding, other malignant tumors in the past five years.

Outcomes

Primary Outcomes

Tumor size

Evaluating maximum diameter obtained by contrast-enhanced CT scanning

Time frame: 6 months after treatment

Secondary Outcomes

Objective response rate

Percentage of patients whose cancer shrinks or disappears after treatment